Literature DB >> 17165009

[Antiphospholipid syndrome].

C Specker1.   

Abstract

Antiphospholipid syndrome (APS) is characterized by recurrent arterial or venous thromboembolism or pregnancy loss in association with antibodies directed against anionic phospholipids or plasma proteins bound to anionic phospholipids. A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease). In accordance with this, fetal abortion, typically beyond the tenth week of gestation, is also caused by infarctions of blood vessels in the placenta. Establishing the correct diagnosis of APS is not easy. To estimate the risk of thrombotic complications is challenging, as well as the questions of, which, how long and in what strength anticoagulation is recommended. This paper should enable the reader to apply international consensus classification criteria correctly, to interpret the different laboratory tests for anti-phospholipid antibodies and to gain an awareness of the different forms of anticoagulation in order to stratify therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17165009     DOI: 10.1007/s00393-006-0127-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  23 in total

Review 1.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

2.  Primary antiphospholipid syndrome evolving into systemic lupus erythematosus.

Authors:  F Mujic; M J Cuadrado; M Lloyd; M A Khamashta; G Page; G R Hughes
Journal:  J Rheumatol       Date:  1995-08       Impact factor: 4.666

3.  Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients.

Authors:  J L Vianna; M A Khamashta; J Ordi-Ros; J Font; R Cervera; A Lopez-Soto; C Tolosa; J Franz; A Selva; M Ingelmo
Journal:  Am J Med       Date:  1994-01       Impact factor: 4.965

4.  Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.

Authors:  José A Girón-González; Enrique García del Río; Carmen Rodríguez; Javier Rodríguez-Martorell; Ascensión Serrano
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

5.  Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study.

Authors:  C Infante-Rivard; M David; R Gauthier; G E Rivard
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

Review 6.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

7.  Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome.

Authors:  M L Bertolaccini; B Roch; O Amengual; T Atsumi; M A Khamashta; G R Hughes
Journal:  Br J Rheumatol       Date:  1998-11

8.  The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis.

Authors:  T McNally; G Purdy; I J Mackie; S J Machin; D A Isenberg
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

9.  A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

Authors:  D Erkan; Y Yazici; M G Peterson; L Sammaritano; M D Lockshin
Journal:  Rheumatology (Oxford)       Date:  2002-08       Impact factor: 7.580

10.  Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome.

Authors:  M D Hughson; G A McCarty; R A Brumback
Journal:  Hum Pathol       Date:  1995-07       Impact factor: 3.466

View more
  2 in total

1.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

2.  Study on antiphospholipid/anticardioliplin antibodies in women with recurrent abortion.

Authors:  Farideh Akhlaghi; Mohamad Reza Keramati; Mehri Tafazoli
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.